Performance

ATP-SystemStudienlage & Dosis

Phosphagen-System, anaerobe Glykolyse, oxidative Phosphorylierung.

Studienlage in Zahlen

Studien gesamt: 978
Mit Abstract: 15
Meta / Systematic / RCT: 0
Häufig zitiert: 4
Erscheinungsjahre: 1949–2026

ATP-System im Kontext von Performance

Dieses Thema ist Teil unserer Welt „Performance". Dort findest du Methodik, Studienlage und Hebel mit dem größten Effekt — sowie die Reihenfolge, in der sich Hebel sinnvoll aufeinander aufbauen.

Zur Welt Performance

Top-Studien zu ATP-System

Sortiert nach einflussreichen Zitationen und Erscheinungsjahr.

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.
Signal transduction and targeted therapy2023200 einflussreiche Zitationen
Metastatic dissemination of solid tumors, a leading cause of cancer-related mortality, underscores the urgent need for enhanced insights into the molecular and cellular mechanisms underlying metastasis, chemoresistance, and the mechanistic…
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism.
Diabetes & metabolism journal2024165 einflussreiche Zitationen
Glucagon-like peptide-1 (GLP-1) is a 30-amino acid peptide hormone that is mainly expressed in the intestine and hypothalamus. In recent years, basic and clinical studies have shown that GLP-1 is closely related to lipid metabolism, and it…
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1*
Journal of Biological Chemistry2009104 einflussreiche Zitationen
The mammalian target of rapamycin (mTOR) kinase is the catalytic subunit of two functionally distinct complexes, mTORC1 and mTORC2, that coordinately promote cell growth, proliferation, and survival. Rapamycin is a potent allosteric mTORC1…
Dual regulation of the AMP-activated protein kinase provides a novel mechanism for the control of creatine kinase in skeletal muscle.
The EMBO journal199869 einflussreiche Zitationen
The AMP-activated protein kinase (AMPK) is activated by a fall in the ATP:AMP ratio within the cell in response to metabolic stresses. Once activated, it phosphorylates and inhibits key enzymes in energy-consuming biosynthetic pathways,…
5-Hydroxytryptamine 2B receptor antagonism restores ATP and reduces tubulointerstitial fibrosis in the renal cortices of aged mice.
The Journal of pharmacology and experimental therapeutics2026E
Age is a prominent risk factor for the development of kidney disease, emphasizing the importance of understanding and mitigating the mechanisms underlying renal aging. Aging mitochondria in tubular cells become increasingly dysfunctional,…
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
Circulation2014n=27
<h4>Background</h4>The primary objective of this mechanistic open-label, stratified clinical trial was to determine the effect of 8 weeks' sodium glucose cotransporter 2 inhibition with empagliflozin 25 mg QD on renal hyperfiltration in…
AMP-activated protein kinase in metabolic control and insulin signaling.
Circulation research2007
The AMP-activated protein kinase (AMPK) system acts as a sensor of cellular energy status that is conserved in all eukaryotic cells. It is activated by increases in the cellular AMP:ATP ratio caused by metabolic stresses that either…
A Role for AMP-Activated Protein Kinase in Contraction- and Hypoxia-Regulated Glucose Transport in Skeletal Muscle
Molecular Cell2001
Eukaryotic cells possess systems for sensing nutritional stress and inducing compensatory mechanisms that minimize the consumption of ATP while utilizing alternative energy sources. Such stress can also be imposed by increased energy…
ATP receptor-mediated synaptic currents in the central nervous system
Nature1992
Until now, the only well documented, fast excitatory neurotransmitter in the brain has been glutamate. Although there is evidence for adenosine 5'-triphosphate (ATP) acting as a transmitter in the peripheral nervous system, suggestions for…
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
The Lancet2006
<h4>Background</h4>Rimonabant, a selective cannabinoid type 1 receptor blocker, reduces bodyweight and improves cardiovascular and metabolic risk factors in non-diabetic overweight or obese patients. The aim of the RIO-Diabetes trial was…